Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacological control.
Eugui
E M
EM
Roche Bioscience, Palo Alto, California 94304, USA. elsie.eugui@roche.com
D002908:Chronic Disease; D005347:Fibroblasts / Q000276:immunology; D006084:Graft Rejection / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018448:Models, Immunological; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D016211:Transforming Growth Factor alpha / Q000187:drug effects / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000235:genetics*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; D009173:Mycophenolic Acid